Insider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) CEO Buys 8,000 Shares of Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor purchased 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were bought at an average price of $3.77 per share, for a total transaction of $30,160.00. Following the acquisition, the chief executive officer now directly owns 36,257 shares in the company, valued at $136,688.89. This trade represents a 28.31 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Perspective Therapeutics Stock Performance

NYSE CATX traded down $0.29 during trading hours on Wednesday, hitting $3.71. The company had a trading volume of 1,649,662 shares, compared to its average volume of 849,315. Perspective Therapeutics, Inc. has a 1-year low of $2.28 and a 1-year high of $19.05. The business has a 50 day moving average of $10.27 and a 200-day moving average of $12.15.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The firm had revenue of $0.37 million during the quarter. As a group, analysts expect that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Royal Bank of Canada lowered their price objective on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a research note on Monday, November 25th. UBS Group began coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target (down previously from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. Finally, Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.14.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Perspective Therapeutics by 34.6% during the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Perspective Therapeutics in the first quarter worth $138,000. Bank of New York Mellon Corp boosted its holdings in shares of Perspective Therapeutics by 214.0% in the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock valued at $1,369,000 after acquiring an additional 93,548 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of Perspective Therapeutics in the 2nd quarter worth $630,000. Finally, Victory Capital Management Inc. bought a new position in shares of Perspective Therapeutics during the 2nd quarter valued at about $117,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.